EP Patent

EP4616857A1 — Ophthalmological composition comprising aceclidine for treating presbyopia and dosage regimen thereof

Assigned to Lenz Therapeutics Operations Inc · Expires 2025-09-17 · 1y expired

What this patent protects

The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.

USPTO Abstract

The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.

Drugs covered by this patent

Patent Metadata

Patent number: EP4616857A1
Jurisdiction: EP
Classification: —
Expires: 2025-09-17
Drug substance claim: No
Drug product claim: No
Assignee: Lenz Therapeutics Operations Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.